Bio/Pharma News

Oct 11, 2017
By Pharmaceutical Technology Editors
Amgen is seeking approval for an additional indication in glucocorticoid-induced osteoporosis for its blockbuster osteoporosis therapeutic, Prolia.
Oct 04, 2017
By Pharmaceutical Technology Editors
The Danish biotechnology company has been awarded a sole-source BARDA contract valued at more than $539 million for a freeze-dried smallpox vaccine.
Oct 04, 2017
By Pharmaceutical Technology Editors
Under Project BioShield, the agency could provide more than $170 million in funding to purchase and support late-stage development of Ebola vaccines and therapeutic drugs.
Oct 03, 2017
By Pharmaceutical Technology Editors
The alliance gives Celgene an option to acquire programs run by Nimbus Therapeutics for developing therapeutics to treat autoimmune disorders.
Oct 02, 2017
By Pharmaceutical Technology Editors
A grant from the Bill & Melinda Gates Foundation will advance PnuVax’s pneumonia vaccine’s clinical development and biomanufacturing scale-up using a low-cost manufacturing approach.
Sep 28, 2017
By Pharmaceutical Technology Editors
AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, and Eli Lilly and Company said they are working to restore normal operations at their respective facilities and continuing recovery efforts.
Sep 28, 2017
By Pharmaceutical Technology Editors
Amgen will collaborate with China’s Simcere Pharmaceutical Group, a R&D-driven pharmaceutical company, to co-develop four biosimilars for the Chinese market.
Sep 27, 2017
By Pharmaceutical Technology Editors
FDA rejected the company’s biologics license application for its anti-rheumatoid arthritis biologic and has requested additional clinical safety data.
Sep 26, 2017
By Pharmaceutical Technology Editors
Glythera gains exclusive access to Cancer Research UK’s novel CDK11 inhibitor program for the development of ADCs conjugated using its highly stable conjugation platform, PermaLink.
Sep 26, 2017
By Pharmaceutical Technology Editors
This latest FDA approval expands the blockbuster anti-cancer biologic’s indications in oncology.
native1_300x100
lorem ipsum